2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-163348
    FXIIa-IN-4 98.87%
    FXIIa-IN-4 (compound 22) is a potent, selective human FXIIa inhibitor with the IC50 of 0.032 μM, 0.30 μM, ＞50 μM for FXIIa, thrombin and FXIa, respectively. FXIIa-IN-4 can be used for study of anticoagulant.
    FXIIa-IN-4
  • HY-17356R
    Fenofibrate (Standard) 49562-28-9 99.91%
    Fenofibrate (Standard) is the analytical standard of Fenofibrate. This product is intended for research and analytical applications. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
    Fenofibrate (Standard)
  • HY-173572
    SKLB-11A 433953-86-7 99.40%
    SKLB-11A is a selective, orally active and allosteric SIRT3 (sirtuin 3) agonist with a Kd value of 4.7 μM. SKLB-11A is highly selective for other members of the SIRT family. SKLB-11A activates autophagy-related signaling pathways, prevents mitochondrial dysfunction, improves cardiac function in Doxorubicin (HY-15142A)-induced cardiotoxicity and myocardial ischemia/reperfusion models.
    SKLB-11A
  • HY-17468S
    Bumetanide-d5 1216739-35-3 99.82%
    Bumetanide-d5 is a deuterium labeled Bumetanide. Bumetanide is a selective Na+-K+-Cl- (NKCC1) inhibitor, weakly inhibits NKCC2, with ?IC50s of 0.68 and 4.0 μM for hNKCC1A and hNKCC2A, respectively.
    Bumetanide-d5
  • HY-175032
    ATF3-IN-1 2952703-90-9
    ATF3-IN-1 is a ferroptosis and ATF3 inhibitor. ATF3-IN-1 inhibits oxidative stress and ferroptosis through the ATF3/SLC7A11/GPX4 pathway, exerting anti-ischemic stroke effects. ATF3-IN-1 can attenuate ischemia/reperfusion (I/R) injury and improve neuronal survival. ATF3-IN-1 has neuroprotective effects and can be used to study ischemic stroke.
    ATF3-IN-1
  • HY-B0637S
    Bezafibrate-d6 1219802-74-0 98.0%
    Bezafibrate-d6 is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
    Bezafibrate-d6
  • HY-B0782S
    Acetazolamide-d3 1189904-01-5 99.95%
    Acetazolamide-d3 is deuterium labeled Acetazolamide (HY-B0782). Acetazolamide is a carbonic anhydrase (CA) IX inhibitor with an IC50 of 30 nM for hCA IX. Acetazolamide has diuretic, antihypertensive and anti-gonococcal activities.
    Acetazolamide-d3
  • HY-B1538A
    Bamethan hemisulfate 5716-20-1 ≥98.0%
    Bamethan (DL-Bamethane) hemisulfate is a vasodilator that exhibits significant activity in enhancing blood flow and reducing vascular resistance. Bamethan hemisulfate plays a crucial role in the treatment of cardiovascular conditions by improving oxygen delivery to tissues. Bamethan hemisulfate also aids in the management of hypertension through its relaxing effects on blood vessels.
    Bamethan hemisulfate
  • HY-E70203
    Recombinant aprotinin 9087-70-1
    Recombinant aprotinin is a serine protease inhibitor. Recombinant aprotinin can inhibit trypsin and related proteolytic enzymes.
    Recombinant aprotinin
  • HY-N7395A
    Cyclic ADP-​ribose ammonium ≥99.0%
    Cyclic ADP-ribose ammonium (cADPR ammonium) is a potent second messenger for calcium mobilization that is synthesized from NAD+ by an ADP-ribosyl cyclase. Cyclic ADP-ribose ammonium increases cytosolic calcium mainly by Ryanodine receptor-mediated release from endoplasmic reticulum and also by extracellular influx through the opening of TRPM2 channels.
    Cyclic ADP-​ribose ammonium
  • HY-P1025A
    M40 TFA 98.33%
    M40 TFA is the TFA salt form of M40. M40 TFA is an antagonist or a weak agonist for galanin receptor depending on different subtypes of galanin receptors in the brain, hypothalamus, hippocampus, amygdala and pancreas.
    M40 TFA
  • HY-P1106A
    K41498 TFA 99.40%
    K41498 TFA is a potent and highly selective CRF2 receptor antagonist with Ki values of 0.66 nM, 0.62 nM and 425 nM for human CRF2α, CRF2β and CRF1 receptors respectively. K41498 TFA is an analogues of antisauvagine-30 (aSvg-30), inhibits sauvagine-stimulated cAMP accumulation in hCRF2α- and hCRF2β-expressing cells. K41498 TFA can be used for hypotension study.
    K41498 TFA
  • HY-P1415A
    Norleual TFA 99.93%
    Norleual TFA, an angiotensin (Ang) IV analog, is a hepatocyte growth factor (HGF)/c-Met inhibitor with an IC50 of 3 pM. Norleual TFA is an AT4 receptor antagonist and exhibits potent antiangiogenic activities.
    Norleual TFA
  • HY-P1519B
    Brain Natriuretic Peptide (1-32), rat acetate 98.66%
    Brain Natriuretic Peptide (1-32), rat acetate (BNP (1-32), rat acetate) is a 32 amino acid polypeptide secreted by the ventricles of the heart in response to excessive stretching of heart muscle cells (cardiomyocytes).
    Brain Natriuretic Peptide (1-32), rat acetate
  • HY-P1540A
    Angiotensin III, human, mouse TFA 99.94%
    Angiotensin III, human, mouse (TFA) is an angiotensin.
    Angiotensin III, human, mouse TFA
  • HY-P2090A
    Angiopeptin TFA 2478421-60-0 99.01%
    Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, is a weak sst2/sst5 receptor partial agonist with IC50 values of 0.26 nM and 6.92 nM, respectively. Angiopeptin TFA is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin TFA inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin TFA has the potential for coronary atherosclerosis research.
    Angiopeptin TFA
  • HY-Q22471
    ROCK1-IN-1 692869-38-8 98.86%
    ROCK1-IN-1 is a ROCK1 inhibitor with a Ki value of 540 nM. ROCK1-IN-1 can be used for the research of hypertension, glaucoma and erectile dysfunction.
    ROCK1-IN-1
  • HY-U00437
    Pz-1 1800505-64-9 99.90%
    Pz-1 is a potent RET and VEGFR2 inhibitor with IC50s of less than 1 nM for both wild type kinases.
    Pz-1
  • HY-113341S
    7ß-Hydroxycholesterol-d7 349553-97-5
    7ß-Hydroxycholesterol-d7 is the deuterium labeled 7α-Hydroxycholesterol. 7β-Hydroxycholesterol is an oxysterol that derived by the oxidation of cholesterol. 7β-hydroxycholesterol can induce cellular oxidative stress, apoptosis, and necrosis, resulting in cytotoxicity. 7β-hydroxycholesterol has antitumor activity.
    7ß-Hydroxycholesterol-d7
  • HY-113446S
    Leukotriene C4-d5 1441421-73-3
    Leukotriene C4-d5 is the deuterium labeled Leukotriene C4. Leukotriene C4 is the parent cysteinyl leukotriene produced by the LTC4 synthase catalyzed conjugation of glutathione to LTA4.
    Leukotriene C4-d5
Cat. No. Product Name / Synonyms Application Reactivity